Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
enGene Therapeutics Inc. (NASDAQ: ENGN)
ENGN Stock Predictions and Ratings
WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
BUY
Analyst Forecast (1yr):
400%
ENGN Stock Analysis
ENGN
PE Ratio:
ENGN
PEG Ratio:
Not Available
ENGN
Forward EPS Growth (12 month):
0.00%
ENGN
PS Ratio:
ENGN
PSG Ratio:
Not Available
ENGN
Forward Revenue Growth (12 month):
0.00%
ENGN Articles
No data was found